DL
Therapeutic Areas
PeproMene Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PMB-CT01 (PMB-101) | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) | Phase 1 |
| PMB-CT01 (PMB-102) | Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) | Phase 1 |
| BAFFR Allo CAR-NK Cells | B-cell malignancies | Pre-clinical |
| BAFF-R/CD3 Bispecific mAb | B-cell malignancies, Autoimmune Disorders | Pre-clinical |